Fertin Pharma develops and manufactures pharmaceutical and nutraceutical products for leading global companies to support healthier living

Fertin Pharma helps customers create effective, convenient and pleasant high-quality products based on their innovative oral and intra-oral delivery systems including compressed and extruded gum, lozenges, ZapLiq® and pouch powder.

Fertin’s product portfolio has a broad variety of current and possible application areas including Nicotine Replacement Therapy, oral care, gastrointestinal, pain and allergy management, cough and cold and much more.

Fertin supports brand owners and retailers through partners in developing new and innovative products. As an example, its unique combination of more than 100 years of confectionary heritage, profound nicotine knowledge and pharma manufacturing capabilities has made the company the largest independent manufacture of medicated chewing gum in the world.

The company employs more than 700 people across R&D centers and manufacturing facilities in Canada, India and Denmark.

EQT acquired Fertin Pharma in January 2017 and thus entered a partnership with the Bagger-Sørensen family, who still holds a 30% interest in the company.

 To Fertin Pharma

Market trends and Drivers 

Fertin Pharma is positioned in the attractive CDMO space that is supported by the continued outsourcing trend in the pharmaceutical and nutraceutical industries.

Fertin’s addressable markets are further supported by global mega trends such as i) increasing government scrutiny of smoking due to growing healthcare costs, ii) more stringent regulations, iii) increased health awareness and spend on consumer health, and iv) shifting wealth and rise of the middle class in emerging markets.

Investment potential

Through an innovative and global CDMO profile built from a vision of encouraging healthier living, Fertin engages in partnerships with leading pharmaceutical and consumer goods companies across the world. The value creation plan is focused on strengthening the business with these customers and solidifying the smoking cessation business, whilst commercializing new and innovative development opportunities with existing and new customers.

Additionally, the plan includes building geographic coverage through relevant regulatory filings and local commercial partnerships throughout the developed and developing world.

Societal contribution

The icons illustrate the portfolio companies' positive societal contributions based on their solutions i.e. how their products and/or services solve key challenges expressed as the Sustainable Development Goals (SDGs)

Board of Directors

Marianne Kirkegaard Chairperson
Rikke Kjær Nielsen Board member
Manfred Scheske Board member
Lars Bang Board member
Claus Bagger-Sørensen Board member
Frank Condella Board member


Peter Halling CEO
Michael Thomsen CFO